Substance Use During Pregnancy: Risks and Treatment

Substance use during pregnancy presents complex clinical and ethical considerations that require careful, non-judgmental care. The risks are real and well-documented, but the approach to treatment must prioritize both the health of the pregnant individual and the developing fetus, recognizing that punitive approaches drive people away from the care they need. Pregnancy is often a powerful motivator for seeking treatment, and when appropriate support is available, outcomes for both parent and child improve substantially. This guide covers the risks associated with specific substances during pregnancy, evidence-based treatment approaches, NJ-specific resources, and what neonatal abstinence syndrome means in practice.

Key Takeaways

• Substance use during pregnancy affects fetal development differently depending on the substance, the timing of exposure, and the amount and duration of use
• For opioid use disorder during pregnancy, medication-assisted treatment with buprenorphine or methadone is the standard of care; abrupt opioid withdrawal during pregnancy carries greater risk than continued MAT
• New Jersey does not criminalize substance use during pregnancy, and NJ Medicaid provides expanded coverage for prenatal addiction treatment
• Neonatal abstinence syndrome (NAS) is a treatable and manageable condition; it is not a permanent injury
• Stigma and fear of legal consequences are the primary barriers to treatment during pregnancy; clinical environments that address these fears improve engagement

Substance Use Disorder During Pregnancy

Substance use during pregnancy is more common than many people realize and spans every demographic group. Understanding the specific risks by substance helps inform treatment decisions without descending into fear-based messaging.

Scope of the Problem

SAMHSA’s National Survey on Drug Use and Health provides data on substance use among pregnant individuals, though the numbers are likely underestimates due to underreporting. The survey consistently finds that alcohol, tobacco, and cannabis are the most commonly used substances during pregnancy, with opioids, stimulants, and benzodiazepines representing smaller but clinically significant populations.

The circumstances surrounding substance use during pregnancy vary widely. Some individuals used substances before becoming aware of the pregnancy. Others have pre-existing substance use disorders that pregnancy does not automatically resolve. Some develop opioid dependence through prescribed pain medication. Reducing this issue to a simple narrative of irresponsibility ignores the clinical reality, which is that substance use disorder is a medical condition that persists regardless of pregnancy status.

Common Substances and Their Risks

Alcohol remains the substance with the most extensively documented fetal effects. Fetal alcohol spectrum disorders (FASD) encompass a range of outcomes from mild cognitive effects to fetal alcohol syndrome, characterized by facial abnormalities, growth restriction, and central nervous system damage. No safe level of alcohol consumption during pregnancy has been established, which is the basis for clinical guidelines recommending complete abstinence.

Opioids, including prescription painkillers, heroin, and fentanyl, cross the placenta and can cause physical dependence in the fetus. The primary concern is neonatal abstinence syndrome (NAS), a withdrawal syndrome that occurs in the newborn after delivery. Importantly, NAS is treatable and does not indicate permanent damage.

Stimulants, including cocaine and methamphetamine, are associated with placental abruption, preterm birth, low birth weight, and potential neurodevelopmental effects. The evidence on long-term outcomes is more nuanced than early media coverage suggested; the “crack baby” narrative of the 1980s and 1990s has been substantially revised by subsequent research.

Benzodiazepines carry risks of neonatal sedation, respiratory depression, and a withdrawal syndrome in the newborn. Abrupt discontinuation during pregnancy is not recommended due to seizure risk in the pregnant individual; supervised tapering under medical care is the appropriate approach.

Cannabis use during pregnancy is associated with lower birth weight and potential effects on neurodevelopment, though the research base is still evolving. The increasing potency of commercial cannabis products raises additional concerns that earlier studies may not fully capture.

Treatment Approaches for Pregnant Individuals

Treatment for substance use disorder during pregnancy follows the same evidence-based principles as treatment for any population, with important modifications for the specific clinical context.

Medication-Assisted Treatment in Pregnancy

For pregnant individuals with opioid use disorder, medication-assisted treatment (MAT) with buprenorphine or methadone is the standard of care endorsed by ACOG (American College of Obstetricians and Gynecologists), SAMHSA, and the World Health Organization. This recommendation reflects a clinical reality that is sometimes counterintuitive: continuing MAT during pregnancy produces better outcomes for both parent and fetus than attempting detoxification.

Abrupt opioid withdrawal during pregnancy carries risks of fetal distress, preterm labor, and fetal death. These risks are higher than the manageable risk of neonatal abstinence syndrome associated with continued MAT. Buprenorphine (often prescribed as Subutex, the formulation without naloxone, during pregnancy) has been associated with less severe NAS than methadone in some studies, though both are considered acceptable.

The decision between buprenorphine and methadone should be individualized based on the person’s treatment history, the severity of opioid use disorder, and practical factors such as access to methadone clinics versus office-based buprenorphine prescribers. For additional information on medication-assisted treatment, that guide covers the broader evidence base.

Behavioral Therapies Adapted for Perinatal Care

Cognitive behavioral therapy (CBT) and contingency management have demonstrated effectiveness in pregnant populations. Contingency management, in which vouchers or incentives are provided for drug-free urine screens and kept prenatal appointments, has shown particular promise in perinatal addiction treatment because it reinforces both abstinence and engagement with prenatal care simultaneously.

Motivational interviewing is valuable during pregnancy because ambivalence about treatment is common. The pregnant individual may simultaneously want to stop using substances and feel unable to do so, or may worry that seeking treatment will trigger legal consequences or child welfare involvement. A motivational approach that validates these concerns while supporting movement toward treatment engagement is more effective than confrontational methods.

Group therapy with other pregnant individuals or new parents in recovery provides peer support from people who understand the specific challenges of this situation. Parenting skills training and perinatal health education can be integrated into group programming.

NJ Programs and Resources for Pregnant Individuals

New Jersey has several features in its behavioral health and legal systems that make it a relatively accessible state for pregnant individuals seeking addiction treatment.

Perinatal Addiction Treatment in New Jersey

NJ’s Division of Mental Health and Addiction Services (DMHAS) funds several programs specifically designed for pregnant individuals with substance use disorders. These programs integrate addiction treatment with prenatal medical care, providing a comprehensive approach that addresses both conditions in a single setting.

Several residential treatment programs in New Jersey accept pregnant women and provide obstetric coordination, nutritional support, and parenting preparation alongside addiction treatment. These programs recognize that stable housing, medical care, and addiction treatment must be provided together for this population.

New Jersey does not criminalize substance use during pregnancy. This legal framework is significant because fear of prosecution is one of the most common reasons pregnant individuals avoid seeking treatment. NJ law focuses on treatment access rather than punishment, and healthcare providers are encouraged to screen for substance use and offer referrals rather than report to law enforcement.

NJ Medicaid Coverage for Prenatal SUD Treatment

NJ Medicaid covers substance abuse treatment for pregnant women, with expanded eligibility that extends coverage to individuals who may not otherwise qualify. This includes both outpatient and residential treatment services. The NJ FamilyCare program provides coverage for prenatal care, substance abuse treatment, and mental health services, often with no cost-sharing for pregnant enrollees.

For individuals who need assistance navigating Medicaid enrollment or finding covered treatment programs, NJ Medicaid rehab coverage provides detailed information. The NJ addiction services hotline can also assist with identifying programs that accept Medicaid and have openings for pregnant individuals.

Neonatal Abstinence Syndrome and Postnatal Care

Neonatal abstinence syndrome (NAS) is one of the most anxiety-provoking aspects of substance use during pregnancy for parents and is frequently misunderstood in public discourse.

What NAS Is and How It Is Managed

NAS occurs when a newborn who was exposed to opioids (or certain other substances) in utero experiences withdrawal symptoms after birth. Symptoms typically appear within 24 to 72 hours of delivery and may include high-pitched crying, tremors, feeding difficulties, irritability, sleep disturbances, and in some cases, seizures.

NAS is a treatable condition. The Finnegan Neonatal Abstinence Scoring System is widely used to assess symptom severity and guide treatment decisions. Mild NAS is often managed with non-pharmacological interventions: swaddling, reduced stimulation, frequent small feedings, skin-to-skin contact, and a calm environment. Moderate to severe NAS may require pharmacological treatment, typically with morphine or methadone, administered in gradually decreasing doses over days to weeks.

The critical point is that NAS, while requiring medical management, is not a permanent condition. Infants who receive appropriate treatment recover, and long-term developmental outcomes are influenced far more by the postnatal environment, including parenting quality, stability, and continued parental recovery, than by NAS itself.

Postpartum Recovery Support

The postpartum period is a high-risk time for relapse. Sleep deprivation, hormonal shifts, the stress of newborn care, and the psychological adjustment to parenthood all increase vulnerability. Continued addiction treatment through this period is essential, not optional.

Postpartum treatment planning should include continued medication-assisted treatment if applicable, access to mental health screening for postpartum depression and anxiety, peer support through recovery groups for parents, and practical support including housing assistance, childcare, and parenting education.

Child welfare involvement, when it occurs, should be oriented toward family preservation and treatment support rather than separation. NJ’s approach emphasizes keeping families together when the parent is engaged in treatment and the child is safe, recognizing that parental recovery and family stability produce the best outcomes for children.

For those exploring other aspects of addiction in specific populations, our guides on addiction in older adults and LGBTQ+ communities and bipolar disorder and substance abuse address related dual diagnosis topics.

This article is part of our complete guide to dual diagnosis and co-occurring mental health disorders.